Thursday, November 10, 2016

AstraZeneca drops early head and neck cancer drug plans

LONDON, Nov 10 (Reuters) - AstraZeneca said on

Thursday it had given up on the idea of seeking an early

approval of its immunotherapy drug durvalumab in head and neck

cancer using mid-stage Phase II...

Read more
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)